MacroGenics Enterprise Value Over E B I T D A from 2010 to 2024

MGNX Stock  USD 3.41  0.07  2.10%   
MacroGenics Enterprise Value Over EBITDA yearly trend continues to be fairly stable with very little volatility. Enterprise Value Over EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, MacroGenics Enterprise Value Over EBITDA regression line of annual values had significance of  0.15 and arithmetic mean of  40.52. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
262.15859433
Current Value
275.27
Quarterly Volatility
98.41154365
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MacroGenics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MacroGenics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.3 M, Interest Expense of 1.5 M or Selling General Administrative of 37 M, as well as many indicators such as Price To Sales Ratio of 9.98, Dividend Yield of 0.0 or PTB Ratio of 4.1. MacroGenics financial statements analysis is a perfect complement when working with MacroGenics Valuation or Volatility modules.
  
Check out the analysis of MacroGenics Correlation against competitors.
For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

Latest MacroGenics' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of MacroGenics over the last few years. It is MacroGenics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MacroGenics' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

MacroGenics Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean40.52
Coefficient Of Variation242.90
Mean Deviation67.20
Median(2.41)
Standard Deviation98.41
Sample Variance9,685
Range321
R-Value0.39
Mean Square Error8,835
R-Squared0.15
Significance0.15
Slope8.60
Total Sum of Squares135,588

MacroGenics Enterprise Value Over E B I T D A History

2024 275.27
2023 262.16
2022 -3.13
2021 -4.53
2020 -8.89
2019 -2.41
2018 -1.85

About MacroGenics Financial Statements

MacroGenics investors use historical fundamental indicators, such as MacroGenics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in MacroGenics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 262.16  275.27 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.